# A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.

> **NCT00720408** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 48 (actual)

## Conditions studied

- Liver Transplantation
- Transplantation Immunology
- Host vs Graft Reaction

## Interventions

- **DRUG:** Prograf-XL
- **DRUG:** Prograf
- **DRUG:** MMF

## Key facts

- **NCT ID:** NCT00720408
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2009-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00720408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00720408, "A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00720408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*